Glenmede Investment Management, LP Moon Lake Immunotherapeutics Transaction History
Glenmede Investment Management, LP
- $19.8 Trillion
- Q2 2025
A detailed history of Glenmede Investment Management, LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Glenmede Investment Management, LP holds 6,635 shares of MLTX stock, worth $60,776. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,635Holding current value
$60,776% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
157Shares Held
54.5MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$181 Million36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$77.8 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$38 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$23.9 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$15.3 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $338M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...